Last reviewed · How we verify
VRC-HIVMAB0121-00-AB
VRC-HIVMAB0121-00-AB is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 1 development.
At a glance
| Generic name | VRC-HIVMAB0121-00-AB |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VRC-HIVMAB0121-00-AB CI brief — competitive landscape report
- VRC-HIVMAB0121-00-AB updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about VRC-HIVMAB0121-00-AB
What is VRC-HIVMAB0121-00-AB?
VRC-HIVMAB0121-00-AB is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID).
Who makes VRC-HIVMAB0121-00-AB?
VRC-HIVMAB0121-00-AB is developed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).
What development phase is VRC-HIVMAB0121-00-AB in?
VRC-HIVMAB0121-00-AB is in Phase 1.